芝加哥大学研究人员基于超过10年的全国代表性数据发现，GLP-1药物（如Ozempic）虽然能够改善血糖控制、降低心血管风险和减轻体重，但在心理健康、就业和婚姻状况等生活领域的改善效果甚微1。该研究由芝加哥大学哈里斯公共政策学院的Robert Kaestner和Cuiping Schiman主持，分析了2012年至2023年期间患有糖尿病的成年人数据1。
研究人员在跟踪同一个体随时间变化后发现，GLP-1用户与非使用者在抑郁症状、心理压力、自评健康、就业和婚姻状况方面的差异基本消失1。无论观察约1年还是2年的GLP-1用药周期，药物对更广泛生活结果的影响都甚微1。这表明该类药物的生活影响可能比其显著的身体健康益处更为微妙1。
Researchers at the University of Chicago have found that while GLP-1 medications such as Ozempic effectively improve blood sugar control, reduce cardiovascular risk, and promote weight loss, their benefits appear to extend little beyond physical health outcomes.1 The study, which analyzed more than a decade of nationally representative data spanning 2012 to 2023, tracked adults with diabetes and examined changes in depression symptoms, psychological stress, self-rated health, employment status, and marital status.1
The research team, led by Robert Kaestner and Cuiping Schiman from the University of Chicago Harris School of Public Policy, found that when tracking the same individuals over time, differences in psychological health, self-rated health, employment, and marital status between GLP-1 users and non-users essentially disappeared.1 The findings held regardless of whether researchers observed outcomes after approximately one year or two years of medication use, suggesting that the drugs' influence on broader life outcomes remains minimal.1 The results indicate that despite the substantial physical health improvements these medications deliver, their impact on overall quality of life may be more subtle than their dramatic body-changing effects suggest.1
评论
还没有评论，欢迎留下第一条。